MG
BSX icon

Michael Gelband’s Boston Scientific BSX Stock Holding History

Michael Gelband’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6M Buy
504,948
+193,585
+62% +$10.5M 0.14% 116
2026
Q1 		$19.5M Buy
311,363
+138,963
+81% +$11.1M 0.16% 107
2025
Q4 		$16.4M Sell
172,400
-30,250
-15% -$2.97M 0.13% 136
2025
Q3 		$19.8M Sell
202,650
-553,217
-73% -$57.3M 0.2% 91
2025
Q2 		$81.2M Buy
755,867
+194,602
+35% +$19.7M 0.71% 16
2025
Q1 		$56.6M Buy
561,265
+257,901
+85% +$26M 0.56% 21
2024
Q4 		$27.1M Sell
303,364
-700,160
-70% -$61.6M 0.19% 87
2024
Q3 		$84.1M Buy
1,003,524
+323,831
+48% +$25.5M 0.51% 24
2024
Q2 		$52.3M Buy
679,693
+451,884
+198% +$33.1M 0.36% 35
2024
Q1 		$15.6M Buy
+227,809
New +$14.6M 0.12% 136
2023
Q3 		– Sell
-362,484
Closed -$19.6M – 1725
2023
Q2 		$19.6M Buy
362,484
+201,709
+125% +$10.5M 0.16% 112
2023
Q1 		$8.04M Buy
+160,775
New +$7.58M 0.07% 353
2022
Q3 		– Sell
-92,295
Closed -$3.44M – 1897
2022
Q2 		$3.44M Sell
92,295
-88,212
-49% -$3.59M 0.04% 550
2022
Q1 		$8M Buy
180,507
+89,134
+98% +$3.86M 0.1% 247
2021
Q4 		$3.88M Sell
91,373
-26,753
-23% -$1.12M 0.04% 524
2021
Q3 		$5.13M Buy
118,126
+56,649
+92% +$2.51M 0.07% 392
2021
Q2 		$2.63M Sell
61,477
-72,020
-54% -$3.03M 0.03% 558
2021
Q1 		$5.16M Sell
133,497
-110,976
-45% -$4.2M 0.08% 258
2020
Q4 		$8.79M Buy
244,473
+227,754
+1,362% +$8.21M 0.09% 143
2020
Q3 		$639K Sell
16,719
-121,691
-88% -$4.69M 0.01% 887
2020
Q2 		$4.86M Buy
138,410
+19,304
+16% +$695K 0.13% 166
2020
Q1 		$3.89M Buy
119,106
+113,148
+1,899% +$4.42M 0.21% 81
2019
Q4 		$269K Sell
5,958
-15,434
-72% -$646K 0.01% 1206
2019
Q3 		$870K Buy
+21,392
New +$906K 0.03% 430

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Michael Gelband's BSX Position: Q2 2026 in Review

Michael Gelband increased its Boston Scientific (BSX) stake by 62% in Q2 2026, buying an estimated $10.5M and bringing the position to 504,948 shares worth $21.6M. The position accounts for 0.14% of the portfolio, ranked #116.

Michael Gelband first reported a position in BSX in Q3 2019 and has held it in 24 quarters since. The position peaked at $84.1M in Q3 2024. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Michael Gelband held 504,948 shares of Boston Scientific worth $21.6M as of Q2 2026.
  • Michael Gelband bought 193,585 Boston Scientific shares in Q2 2026, an estimated $10.5M.
  • Boston Scientific made up 0.14% of Michael Gelband's portfolio in Q2 2026, its #116 holding.
  • Michael Gelband first reported a position in Boston Scientific in Q3 2019 and has held it in 24 quarters since.
  • Michael Gelband's Boston Scientific position peaked at $84.1M in Q3 2024.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.